Candace S. Matthews
Known title: DirectorCIK: 0001664944
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MillerKnoll Trims Fiscal 2027 Guidance Despite Earnings Beat. MillerKnoll reported Q1 earnings that beat estimates, supported by an orders rebound and margin expansion. However, the company lowered its full-year fiscal 2027 outlook, citing softer revenue trends. This mixed result highlights a tension between current operational strength and future demand expectations.
Transaction History
| ATR | ▲ Buy | Grant | 226 | $0 | 7/16/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,552 | $0 | 5/6/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,253 | $0 | 5/7/2025 | View on chart |
| MLKN | ▲ Buy | Grant | 5,479 | $120K | 1/15/2025 | View on chart |
| ATR | ▲ Buy | Grant | 1,304 | $0 | 5/1/2024 | View on chart |
| MLKN | ▲ Buy | Grant | 6,773 | $172K | 1/15/2024 | View on chart |
| ATR | ▲ Buy | Grant | 1,435 | $0 | 5/3/2023 | View on chart |
| MLKN | ▲ Buy | Grant | 5,059 | $115K | 1/15/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,302 | $0 | 5/4/2022 | View on chart |
| MLKN | ▲ Buy | Grant | 4,619 | $172K | 1/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage
AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.